

Form PTO 1449
(Modified)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY DOCKET NO.
244288US0DIVSERIAL NO. 10/690671
New Application

LIST OF REFERENCES CITED BY APPLICANT

APPLICANT

Hiroyuki ISHIWATA, et al.

FILING DATE

Herewith October 23, 2003

GROUP

1624

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						
	AM						
	AN						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AO	1-106810	04/24/89	JAPAN (w/English abstract)		xx
	AP	7-047506	03/01/85	JAPAN (w/English abstract)		xx
	AQ	8-092216	04/09/96	JAPAN (w/English abstract)		xx
	AR	8-100177	04/30/96	JAPAN (w/English abstract)		xx
	AS	10-324631	12/08/98	JAPAN (w/English abstract)		xx
	AT	11-269192	10/05/99	JAPAN (w/English abstract)		xx
	AU	59-167564	09/21/84	JAPAN (w/English abstract)		xx
	AV	WO 96/11682	1996	WIPO (corr. EP 0 707 491)		

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)

BC	AW	Cas printout for Hagen et al., Synthesis and cardiovascular properties of 5-(4-pyridinyl)-, 6-methyl-5-(4-pyridinyl)- and 6-methyl 5-phenyl -substituted 3-cyano-2-aminoalkylaminopyridines, Pharmazie 45: 240-241, 1990.
	AX	Robert B. Fick, Jr., Current Opinion in Pulmonary Medicine, vol. 5, pages 76-80, "ANTI-IgE AS NOVEL THERAPY FOR THE TREATMENT OF ASTHMA", 1999.
	AY	Fahad Imani, Emerging Therapeutic Targets, vol. 3, no. 2, pages 229-240, "EMERGING THERAPEUTIC TARGETS IN ASTHMA AND ALLERGY: MODULATION OF IgE", 1999.
	AZ	Henry Milgrom, et al., The New England Journal of Medicine, vol. 341, no. 26, pages 1966-1973, "TREATMENT OF ALLERGIC ASTHMA WITH MONOCLONAL ANTI-IgE ANTIBODY", December 23, 1999.

☒ Additional References sheet(s) attached

Examiner

Brenda Coleman

Date Considered

Sept. 11, 2006

*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO. 244288US0DIV		SERIAL NO. 10/690671 NEW APPLICATION	
LIST OF REFERENCES CITED BY APPLICANT				APPLICANT Hiroyuki ISHIWATA, et al.			
				FILING DATE HEREWITH October 23, 2003		GROUP 1624	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE	
	AAA						
	AAB						
	AAC						
	AAD						
	AAE						
	AAF						
	AAG						
	AAH						
	AAI						
	AAJ						
	AAK						
	AAL						
	AAM						
	AAN						
FOREIGN PATENT DOCUMENTS							
	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO			
	AAO 0787491	08/08/97	EUROPE				
	AAP WO 98/04508	02/05/98	WIPO (w/English abstract)	xx			
	AAQ WO 98/07702	02/26/98	WIPO (w/English abstract)	xx			
	AAR WO 98/16497	04/23/98	WIPO (w/English abstract)	xx			
	AAS WO 99/19291	04/22/99	WIPO (w/English abstract)	xx			
	AAT WO 99/35140	07/15/99	WIPO				
	AAU WO 99/38829	03/05/99	WIPO (w/English abstract)	xx			
	AAV WO 99/42446	03/26/99	WIPO (w/English abstract)	xx			
	AAW WO 00/05198	02/03/00	WIPO (w/English abstract)	xx			
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)							
	Naosuke Matsuura, et al., Jpn. Pharmacol. Ther., vol. 22, no. 3, pages 1369-1383, "AN IMMUNOPHARMACOLOGICAL STUDY OF (±) [2-[4-(3-ETHOXY-2-HYDROXYPROPOXY)PHENYL]CARBAMOYL]ETHYL]DIMETHYLSULFONIUM P-TOLUENESULFONATE (SUPLATAST TOSILATE, IPD-1151T)", 1994.						
	AAZ						
	AAZ	<input type="checkbox"/> Additional References sheet(s) attached					
Examiner <u>Brenda Coleman</u>				Date Considered <u>Sept. 11, 2006</u>			
*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							